摘要
目的探讨达格列净联合氯沙坦治疗对糖尿病肾病(diabetic nephropathy,DN)患者临床疗效及糖化血红蛋白与肾功能的影响。方法回顾性分析惠安县医院2021年2月—2024年1月收治的81例DN患者临床资料,按照治疗方案分为对照组(氯沙坦治疗,n=39)、试验组(达格列净联合氯沙坦治疗,n=42)。比较两组临床疗效、血糖指标(空腹血糖、餐后2 h血糖、糖化血红蛋白)、肾功能指标(血尿素氮、血肌酐、24 h尿蛋白定量)及不良反应发生情况。结果试验组(90.46%)的总有效率显著高于对照组(74.36%)(P<0.05)。两组治疗后的空腹血糖、餐后2 h血糖、糖化血红蛋白水平均降低,且试验组低于对照组(P<0.05)。两组治疗后的血尿素氮、血肌酐、24 h尿蛋白定量水平均降低,且试验组低于对照组(P<0.05)。试验组的不良反应发生率为14.28%(6/42),对照组的不良反应发生率为10.26%(4/39),两组不良反应发生率比较差异无统计学意义(P>0.05)。结论达格列净联合氯沙坦治疗可提高DN患者的临床疗效,改善糖化血红蛋白与肾功能指标水平,且具有一定安全性。
Objective To investigate the effects of Dapagliflozin combined with Losartan treatment on clinical efficacy and glycosylated hemoglobin and renal function in patients with diabetic nephropathy(DN).Methods Clinical data of 81 DN patients admitted to Hui'an County Hospital from February 2021 to January 2024 were retrospectively analyzed.According to treatment scheme,they were divided into control group(Losartan treatment,n=39)and experimental group(Dapagliflozin combined with Losartan treatment,n=42).Clinical efficacy,blood glucose indexes(fasting blood glucose,postprandial 2 h blood glucose,glycosylated hemoglobin),renal function indexes(blood urea nitrogen,blood creatinine,24 h urinary protein quantification)and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of the experimental group(90.46%)was significantly higher than that of the control group(74.36%)(P<0.05).Fasting blood glucose,postprandial 2 h blood glucose and glycosylated hemoglobin levels were reduced in both groups after treatment,and the experimental group was lower than the control group(P<0.05).After treatment,blood urea nitrogen,blood creatinine and 24 h urinary protein quantitative levels in both groups were decreased,and the experimental group was lower than the control group(P<0.05).The incidence of adverse reactions was 14.28%(6/42)in experimental group and 10.26%(4/39)in control group,and there was no significant difference between the two groups(P>0.05).Conclusion Dapagliflozin combined with Losartan can improve the clinical efficacy of patients with DN,improve the levels of glycosylated hemoglobin and renal function indexes,and has certain safety.
作者
杨志杰
庄小玲
汤红丹
郑水猛
YANG Zhi-jie;ZHUANG Xiao-ling;TANG Hong-dan;ZHENG Shui-meng(Department of Nephrology,Hui'an County Hospital,Hui'an,Fujian,362100,China;Department of Rehabilitation,Quanzhou First Hospital,Quanzhou,Fujian,362000,China;Department of Respiratory Medicine,Hui'an County Hospital,Hui'an,Fujian,362100,China)
出处
《中国血液流变学杂志》
2024年第4期553-556,660,共5页
Chinese Journal of Hemorheology
关键词
达格列净
氯沙坦
糖尿病肾病
临床疗效
糖化血红蛋白
肾功能
Dapagliflozin
Losartan
diabetic nephropathy
clinical efficacy
glycosylated hemoglobin
renal function
